Trial reportInternational journal of radiation oncology, biology, physics2018
Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Trial report in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Simultaneous Versus Sequential IMRT Boost in the Era of Treatment De-Escalation of Head and Neck Cancers.Cancers · 2026Review
- De-escalation of head-and-neck cancer radiotherapy: balancing cure and side effects.Frontiers in oncology · 2026Review
- Reduced Dose and Selective Neck Irradiation Policy in Treating Oropharynx Cancer: Excellent Oncological Outcomes with Very Low Risk of Locoregional Failure.Cancer research and treatment · 2026Article
- Is less more? Revisiting elective nodal irradiation in head and neck cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Review
- Outcomes of Reduced Elective Nodal Radiation Dose and Volume for Laryngeal, Hypopharyngeal, and p16-Negative Oropharyngeal Cancers.Head & neck · 2025Article
- Missed Adjuvant Therapy in Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma.The Laryngoscope · 2025Article
- Automatic segmentation for magnetic resonance imaging guided individual elective lymph node irradiation in head and neck cancer patients.Physics and imaging in radiation oncology · 2024Article
- Detectability and intra-fraction motion of individual elective lymph nodes in head and neck cancer patients on the Magnetic Resonance Image guided linear accelerator.Physics and imaging in radiation oncology · 2024Article
- The Metabolic Footprint of Systemic Effects in the Blood Caused by Radiotherapy and Inflammatory Conditions: A Systematic Review.Metabolites · 2023Review
- Individual elective lymph node irradiation for the reduction of complications in head and neck cancer patients (iNode): A phase-I feasibility trial protocol.Clinical and translational radiation oncology · 2023Article
- Less is more: level IB-sparing radiation therapy in nasopharyngeal cancer.Radiation oncology journal · 2023Article
- Current Evidence of a Deintensification Strategy for Patients with HPV-Related Oropharyngeal Cancer.Cancers · 2022Review
- Review
- MRI visibility and displacement of elective lymph nodes during radiotherapy in head and neck cancer patients.Frontiers in radiology · 2022Article
- Magnetic resonance guided elective neck irradiation targeting individual lymph nodes: A new concept.Physics and imaging in radiation oncology · 2021Article
- Radiotherapy dose-volume parameters predict facial lymphedema after concurrent chemoradiation for nasopharyngeal carcinoma.Radiation oncology (London, England) · 2021Article
- Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer.International journal of particle therapy · 2021Article
- Feasibility of Selective Neck Irradiation with Lower Elective Radiation Dose in Treating Nasopharynx Cancer Patients.Cancer research and treatment · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
purposeTo evaluate a novel chemoradiation therapy (CRT) regimen for patients with squamous cell carcinoma of the head and neck (SCCHN) incorporating a lower intensity modulated radiation therapy dose to electively treated neck lymph nodes than is currently standard. METHODS AND MATERIALS: Eligible patients had locally advanced SCCHN of the oral cavity, oropharynx, larynx, or hypopharynx. The 7-week CRT course consisted of weekly cisplatin at 35 mg/m
resultsBetween 2011 and 2014, 54 patients were enrolled, 31 (57%) of whom had human papillomavirus (HPV)-positive disease. Of the patients, 35 (65%) had stage IVa disease. The median follow-up period for survivors was 36 months (range, 12-66 months). Elective nodal failure did not develop in any patient. The actuarial 3-year survival rate for the entire cohort was 91% (95% confidence interval [CI] 0.79-0.96); for the HPV-negative group, 85% (95% CI 0.61-0.95); and for the HPV-positive group, 96% (95% CI 0.77-0.99). Common grade 3 toxicities were dysphagia (79%), mucositis and/or stomatitis (41%), nausea (20%), xerostomia (13%), vomiting (11%), and neutropenia (10%). The median feeding tube duration was 142 days. Patient FACT-HN scores were higher at 3, 6, and 12 months versus at the end of treatment (P < .0001). Total FACT-HN scores returned to pretreatment baseline by 6 months. Overall QOL-RTI scores were lower from pretreatment to the end of treatment through 12 months (P = .0001).
conclusionsThis CRT regimen for patients with advanced SCCHN demonstrated the potential feasibility of reducing the elective dose to the neck, a topic that requires additional study in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.